The skin represents a physical and chemical barrier against invading pathogens, which is additionally supported by restriction factors that provide intrinsic cellular immunity. These factors detect viruses to block their replication cycle. Here, we uncover the Myb-related transcription factor, partner of profilin (MYPOP) as a novel antiviral protein. It is highly expressed in the epithelium and binds to the minor capsid protein L2 and the DNA of human papillomaviruses (HPV), which are the primary causative agents of cervical cancer and other tumors. The early promoter activity and early gene expression of the oncogenic HPV types 16 and 18 is potently silenced by MYPOP. Cellular MYPOP-depletion relieves the restriction of HPV16 infection, demonstrating that MYPOP acts as a restriction factor. Interestingly, we found that MYPOP protein levels are significantly reduced in diverse HPV-transformed cell lines and in HPV-induced cervical cancer. Decades ago it became clear that the early oncoproteins E6 and E7 cooperate to immortalize keratinocytes by promoting degradation of tumor suppressor proteins. Our findings suggest that E7 stimulates MYPOP degradation. Moreover, overexpression of MYPOP blocks colony formation of HPV and non-virally transformed keratinocytes, suggesting that MYPOP exhibits tumor suppressor properties.

Introduction

The physical and chemical barrier of the skin mediates the first line of defense against invading pathogens. This is additionally supported by the cellular innate immunity [1]. Here, so-called restriction factors detect invading viruses and restrict the viral replication cycle at different stages [1, 2]. For HPV, it is known that a microwound is required to overcome the physical barrier function of the skin to gain access to mitotically active basal cells of the epithelium [3, 4]. However, only a limited number of cellular factors that restrict the viral replication cycle in these cells are identified so far [1, 5].

Human papillomaviruses are small DNA viruses associated with a wide range of benign and malignant epithelial tumors. These viruses account for 5.2% of the worldwide cancer burden [6]. Persistent infections with certain HPV types are the main causative agents for cervical cancer (e.g. HPV16 and 18) and genital warts (e.g. HPV6 and 11) [7, 8]. The virus consists of two capsid proteins comprising the major capsid protein L1 and the minor capsid protein L2, and a double-stranded DNA genome. The genome is subdivided into an early region, a late region, and a noncoding region, the so-called long control region (LCR) or upstream regulatory region [3, 4]. The LCR encompasses about 850 bp containing the major transcription start site of the early promoter, enhancer, and silencer elements. Regulation of early gene expression including expression of the oncogenes E6 and E7 is mediated by binding of cellular and viral factors to the LCR [9–15].
The Myb-related protein MYPOP is a novel intrinsic host restriction factor of oncogenic human...
Results and discussion

MYPOP is a novel interaction partner of the HPV16 L2 protein and the viral DNA

During HPV entry, the minor capsid protein L2 accompanies the viral DNA into the host cell nucleus and is accessible to cytoplasmic and nuclear proteins [20, 23, 24]. Using a Y2H screening approach, we identified novel interaction partners of the HPV16 L2 protein [14, 34–36]. Among others, the Myb-related TF MYPOP was discovered (Fig. 1a) [35]. As this is the first study of human MYPOP, we characterized endogenous, overexpressed and purified MYPOP in immunofluorescence and western blot (WB) analyses (Suppl. Figure 1). MYPOP showed nuclear and cytoplasmic localization and WB bands of about 60 kDa. Co-localization and interaction analyses verified interaction of L2 and MYPOP (Fig. 1b–d). Moreover, we detected association of the incoming virally transduced DNA with the TF MYPOP in the nucleus of infected cells (Fig. 1d).
MYPOP restricts HPV16 PsV infection

The repressive effect of MYPOP on the transfected HPV LCR was extended to incoming histone associated HPV-transduced DNA. For this study, we replaced the viral genome by the pGL4.20 HPV16 LCR plasmid, thereby generating HPV16 LCR PsV. Next, we reduced the endogenous MYPOP level in HaCaT cells by RNA interference. These experiments provided deeper insight into the nature of MYPOP as a novel intrinsic host restriction factor of oncogenic human HPV.
of the TF (Fig. 2 and Suppl. Figure 3). First, four different MYPOP-specific siRNAs led to a reduction of MYPOP mRNA levels without affecting protein amounts and infection when tested 48 h after siRNA transfection (Suppl. Figure 3). Extended incubation times to 4 or 7 days with MYPOP-specific siRNA combined with re-transfection of
Fig. 3 MYPOP is reduced in HPV-transformed cell lines and cancer tissue. a Quantification of MYPOP protein and mRNA in primary keratinocytes (NHEK) and HPV-transformed cell lines HeLa (HPV18), SiHa, and CaSki (both HPV16). Total cellular mRNA was analyzed by quantitative real-time PCR (qPCR). NHEK were set to 100% and data (n = 6) were analyzed using two-tailed unpaired t-test: $p = 0.000944$, $t = -4.6245$, $df = 10$ (HeLa) or Welch two-tailed t-test $p = 0.01839$, $t = -3.3236$, $df = 5.4495$ (SiHa) or two-tailed unpaired t-test $p = 6.653 \times 10^{-3}$, $t = 6.5284$, $df = 10$ (CaSki). Densitometric quantification of the western blots (a representative western blot is shown in the upper panel) was performed with ImageJ software and relative MYPOP band intensities were normalized to β-actin. NHEK cells were set to 100% and data (n = 5) were analyzed using Welch two-tailed t-test $p = 9.81 \times 10^{-7}$, $t = -19.968$, $df = 6.0255$ (HeLa), $p = 9.71 \times 10^{-7}$, $t = 19.949$, $df = 6.035$ (SiHa), $p = 92.11 \times 10^{-7}$, $t = -17.647$, $df = 7.5346$ (CaSki). b Expression of MYPOP in human cervical carcinoma in situ. Human cervical tissue sections were stained for MYPOP (green). Nuclei were counterstained with Hoechst (blue). Scale bar = 10 μm. c HaCaTs were transfected with FLAG-MYPOP without and with 3xHA16E6 as indicated. The cells were lysed to monitor protein expression by western blot using FLAG and HA antibody. Densitometric quantification of western blot data from c. Relative band intensities were assessed by normalizing FLAG-MYPOP levels (# and $)$ to the β-actin using ImageJ software. Control + FLAG-MYPOP-transfected cells were set to 100% for # and for $. Data (n = 9) were analyzed using Welch two-tailed t-test: $p = 0.1431$, $t = -1.5807$, $df = 10.68$ (β-actin) or two-tailed unpaired t-test $p = 0.5826$, $t = -0.5691$, $df = 16$ (β-actin). d Same as c, but cells were transfected with FLAG-MYPOP without and with FLAG-HA-HPV16 E7 as indicated. Densitometric quantification of western blot data was performed as described in c, but FLAG-HA-HPV16 E7. Control + FLAG-MYPOP-transfected cells were set to 100% for # and for $. Data (n = 16) were analyzed using two-tailed unpaired t-test: $p = 6.714 \times 10^{-5}$, $t = 4.6244$, $df = 30$ (β-actin) or Welch two-tailed t-test $p = 3.645 \times 10^{-9}$, $t = 9.583$, $df = 21.241$ (β-actin). The values obtained from three (or six for d) independent experiments are given as boxplots (a, c, d). Due to clarity and conciseness the western blot images are cropped (a, c, d) and the lower panel shows β-actin as a loading control (a, c, d). # represents FLAG-MYPOP of higher molecular weight; $)$ represents FLAG-MYPOP of lower molecular weight ($c, d$); ns, not significant; **$p \leq 0.01$; ***$p \leq 0.001$

The siRNA after 48 h caused a reduction of the endogenous MYPOP protein (Fig. 2a). These findings indicate an unexpected high stability and low turnover rate of the TF and might explain why MYPOP was not detected earlier by siRNA screening. To further increase knockdown efficiency, we used a lentiviral RNAi system. Incubation times of more than 1 week were considerably more successful: all shRNA constructs led to a decrease of MYPOP protein and infectivity was increased by 300–400% compared to control shRNA-treated cells (Fig. 2b), corroborating the antiviral activity of MYPOP on incoming viral DNA.

To verify the negative correlation of the MYPOP expression level and HPV16 PoV infection in different cells, we tested total cellular MYPOP amounts and infection efficiencies of HaCaT cells and primary keratinocytes (NHEK) (Fig. 2c). These results uncovered higher MYPOP expression levels and lower infection rates of NHEK when compared to HaCaT cells. Our data again provide strong evidence that MYPOP limits the infection of human skin cells by HPV16 and acts as a viral restriction factor. Interactions of this factor with other viral promoters may be important in mediating intrinsic immunity against additional viruses.

**MYPOP potently silences HPV16 early gene expression**

As our MYPOP-based ChIP and promoter studies demonstrated binding to the HPV LCR and repression of the LCR activity, we controlled the effect of MYPOP in the whole HPV genome context on the expression of viral early genes. We co-transfected squamous cell carcinoma cells SCC-13 [45] with HPV16 wt (isolate 114B) and FLAG-MYPOP or empty FLAG vector. After 48 h, total cellular RNA was isolated and analyzed for HPV16 E6*I and E1^E4 spliced early transcripts (Fig. 3a). Measurement of these transcripts is the standard method to analyze early gene expression of HPV16 [46–48]. Corroborating our promoter-reporter gene assays, MYPOP reduced HPV16 early genes transcription. These findings strongly support the biological relevance of MYPOP as viral restriction factor. Moreover, the transcriptional suppressor efficiently silences LCR activity even in the absence of L2 and this finding suggests that MYPOP may play a role in different steps of the viral replication cycle, including HPV-induced oncogenesis as the HPV LCR likewise controls the viral oncoproteins E6 and E7.

**MYPOP is eliminated in HPV-transformed cells**

It has been described that early viral oncoproteins E6 and E7, which are expressed in HPV-transformed cells, eliminate detectable tumor suppressors p53 and pRb, respectively [30]. Interestingly, we uncovered that MYPOP protein- but not mRNA levels are almost absent in whole cell lysates of HPV18-transformed HeLa and HPV16-transformed SiHa and CaSki tumor cell lines [49] when compared to primary keratinocytes (Fig. 3a). These results indicate that MYPOP is eliminated in HPV-transformed tumor cells on a post-transcriptional level. This observation was further verified by immunohistochemistry of human cervical carcinoma in situ, where MYPOP expression is present in the keratinocytes of non-lesional cervical tissue (Suppl. Figure 4a), whereas MYPOP expression is almost absent in the carcinoma and only detectable in the non-transformed peripheral keratinocytes (Fig. 3b).

**The HPV16 onco-protein E7 induces downregulation of MYPOP**

The high-risk HPV E6 or E7 oncoproteins are potential candidates to induce MYPOP downregulation. These proteins are highly expressed in HPV-induced cancers and possess the
ability to target tumor suppressors for degradation [5, 30, 50–52]. Importantly, our quantitative western blot analyses demonstrated that overexpression of HPV16 E6 protein had no effect on MYPOP protein amounts (Fig. 3c), whereas HPV16 E7 significantly reduced MYPOP expression levels (Fig. 3d). Together these data provide strong indication that the absence of MYPOP detected in HPV-transformed tumor cell lines and in cervical cancer tissues results from the expression of the papillomaviral oncogene E7.

MYPOP suppresses colony formation of tumor cells

The maintenance of early gene expression is a precondition for proliferation and survival of HPV-induced cancer cells [53–55] and seems to be linked to the decreased MYPOP levels. On the other hand, re-expression of MYPOP might result in reduced cell growth. We therefore overexpressed MYPOP in HPV-transformed SiHa and HeLa cells and tested arrest of proliferation in microscopy analyses or standard quantitative colony formation assays, as described previously [56, 57]. Indeed, MYPOP-GFP-expressing cells displayed altered cell morphology and no tendency to form colonies (Suppl. Figure 4b). Furthermore, expression of MYPOP significantly reduced the number of cells measured by analyzing the area of formed colonies (Fig. 4a, b). MYPOP and GFP-MYPOP expression displayed comparable effects in the colony formation assays. Taken together, our data provide strong indication that MYPOP act as a tumor suppressor in HPV-induced cancer.

MYPOP’s repressive activity might be explained by competition of MYPOP with activating TFs. For c-Myb, it has been shown earlier that it binds to one MRE in the HPV16 LCR and activates early gene expression [11]. Therefore, we conclude that c-Myb and MYPOP might be
opponents in HPV-associated carcinogenesis as (i) both proteins bind to the same DNA motifs, (ii) cause contradicting effects on the HPV16 LCR, and (iii) are inversely regulated (c-Myb protein level is elevated and MYPOP is reduced) in HPV-transformed cells. As c-Myb has been described as proto-oncogene [58], MYPOP might function as a more general tumor suppressor. Indeed, the expression of MYPOP in non-virally transformed HaCaT cells led to a significant reduction of formed colonies (Fig. 4c), supporting the anti-proliferative tumor suppressor function of the Myb-related TF MYPOP.

Overall, our study provides first indications for the so far unknown roles of MYPOP by demonstrating that this Myb-related protein senses incoming viruses and represses viral gene transcription. Thereby, MYPOP acts as a restriction factor and limits cells' permissiveness to infection with oncogenic HPV viruses. Mechanistically, we propose a model in which MYPOP senses incoming oncogenic HPV by interaction with the accessible cytoplasmic part of the L2 protein until release of the viral DNA within the nucleus. Subsequently, MYPOP binds to the LCR via its DBD. This results in silencing of HPV early/oncogene expression and subsequently, suppression of cancer. During cell transformation, the HPV16 onco-protein E7 mediates degradation of MYPOP by a mechanism that is yet to be determined, which results in increased expression of the early viral genes, cell proliferation, and finally oncogenesis. A detailed investigation and elucidation of this transcriptional repressor will be crucial for better understanding of infections by oncogenic papillomaviruses and tumor suppression in general.

Acknowledgements We thank Dr. Hans-Jürgen Butt, Dr. Kaloian Koynov, and Dr. Ulrike Wieland for helpful discussion. We are grateful to Marc A. Schneider and Gilles Spoden for initial experiments (Y2H screening), Karl Sotlar for CIS sections, Claudia Simon for providing the E6 plasmid, Caroline Manicam and Monika Wiedmann for proofreading this manuscript. The skillful technical assistance in lentiviral RNAi system of Aleksandra Dimitrijevic is gratefully acknowledged. This work, including the efforts of Elena Wüstenhagen and Inka Negwer, was funded by the Max Planck Graduate Center together with the Johannes Gutenberg-University Mainz (MPGC). Luise Florin receives research support from the Deutsche Forschungsgemeinschaft (DFG; FL 696/2-1).

Author contributions E.W. and L.F. designed the experiments. E.W., F.B., I.N., F.S., and L.F. performed the experiments and analyzed the data. E.W., K.R., and L.F. wrote the manuscript.

Compliance with ethical standards

Ethics statement Human cervical tissue slices were obtained from excess patient material from the University Medical Center of Mainz and Tübingen with permission from the German ethics committee (837.498.11 (8040)).

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kawamura T, Ogawa Y, Aoki R, Shimada S. Innate and intrinsic antiviral immunity in skin. J Dermatol Sci. 2014;75:159–66.
2. Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol. 2012;12:687–95.
3. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl. 5):F55–70.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.
5. Porter SS, Stepp WH, Stamos JD, McBride AA. Host cell restriction factors that limit transcription and replication of human papillomavirus. Virus Res. 2017;231:10–20.
6. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53 (Suppl. 1):S12–21.
7. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl. 1):2–23.
8. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117:S5–10.
9. Ishiji T, Lace MJ, Parkkinen S, Anderson RD, Haugen TH, Cripe TP, et al. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO J. 1992;11:2271–81.
10. Hoppe-Seyler F, Butz K. Cellular control of human papillomavirus oncogene transcription. Mol Carcinog. 1994;10:134–41.
11. Nürnberg W, Artuc M, Nawrath M, Lovric J, Stüting S, Moelling K, et al. Human c-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res. 1995;55:4432–7.
12. Baldwin A, Hypes MK, Pirisi L, Creek KE. NFI is an essential positive transcription factor for human papillomavirus type 16 early gene expression. Open Virol. 2007;1:33–8.
13. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology. 2009;384:375–9.
14. Schneider MA, Scheller KD, Bund T, Bouchallouk F, Lambert C, Cotarello C, et al. The Transcription Factors TBX2 and TBX3 interact with HPV16 L2 and repress the long control region of human papillomaviruses. 2013. https://doi.org/10.1128/VI.01803-12.
15. Bernard H-U. Regulatory elements in the viral genome. Virology. 2013;455:197–204.
16. Raff AB, Woodham AW, Raff LM, Skete JG, Yan L, Da Silva DM, et al. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013;87:6062–72.
17. Fast LA, Lieber D, Lang T, Florin L. Tetraspanins in infections by human cytomegalo- and papillomaviruses. Biochem Soc Trans. 2017;45:489–97.
18. Scheffer KD, Berditchevski F, Florin L. The tetraspan CD151 in papillomavirus infection. Viruses. 2014;6:893–908.
19. Gräuel L, Fast LA, Scheffer KD, Boukhallouk F, Spoden GA, Tenzer S, et al. The CD63-Syntenin-1 complex controls post-endocytic trafficking of oncopgenic human papillomaviruses. Sci Rep. 2016;6:32337.
20. Florin L, Sapp M, Spoden GA. Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol. 2012;201:437–48.
21. Wang JW, Roden RBS. L2, the minor capsid protein of papillomavirus. Virology. 2013;445:175–86.
22. Bund T, Spoden GA, Koynov K, Hellmann N, Boukhallouk F, Arnold P. A L2 SUMO interacting motif is important for pML-localization and infection of human papillomavirus type 16. Cell Microbiol. 2014. https://doi.org/10.1111/cmi.12271.
23. DiGiuseppe S, Bienkowska-Haba M, Guion LG, Sapp M. Cruising the cellular highways: how human papillomavirus travels from the surface to the nucleus. Virus Res. 2017;231:1–9.
24. Campos SK. Subcellular trafficking of the papillomavirus genome during initial infection: the remarkable abilities of minor capsid protein L2. Viruses. 2017;9:370.
25. McBride AA. The papillomavirus E2 proteins. Virology. 2013;445:57–79.
26. Dreer M, van de Poel S, Stubenrauch F. Control of viral replication and transcription by the papillomavirus E8/E2 protein. Virus Res. 2017;231:96–102.
27. Maglemann GA, Doorbar J. The biology of papillomavirus latency. Open Virol J. 2012;6:190–7.
28. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–60.
29. Yim E-K, Park J-S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37:319–24.
30. Tomaï V. Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers (Basel). 2016;8:95.
31. Gariglio P, Organista-Nava J, Alvarez-Rios E. Role of HR-HPVs E6 and E7 oncoproteins in cervical carcinogenesis. J Mol Genet Med. 2016;10:1–11.
32. McBride AA. Mechanisms and strategies of papillomavirus replication. Biol Chem. 2017. https://doi.org/10.1515/hz-2017-0113.
33. Lederer M, Jockusch BM, Rothkegel M. Profilin regulates the activity of p52POP, a novel Myb-related transcription factor. J Cell Sci. 2005;118:331–41.
34. Schneider MA, Spoden GA, Florin L, Lambert C. Identification of the dynein light chains required for human papillomavirus infection. Cell Microbiol. 2011;13:32–46.
35. Schneider MA. Identifizierung und Charakterisierung zellulärer Interaktionspartner des minoren Kapsidproteins L2 des Humanen Papillomavirus 16. 2011; 1–154. https://publications.unib-mainz.de/theses/volltexte/2016/100000798/pdf/100000798.pdf
36. Wüstenhagen E, Hampe L, Boukhallouk F, Schneider MA, Spoden GA, Negewi I, et al. The Cytoskeletal Adaptor Obscurin-Like 1 interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and is required for HPV16 endocytosis. J Virol. 2016;90:10629–41.
37. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314:111–4.
38. DiGiuseppe S, Keiffer TR, Bienkowska-Haba M, Lusczew M, Guion LGM, Müller M, et al. Topography of the human papillomavirus minor capsid protein L2 during vesicular trafficking of infectious entry. J Virol. 2015;89:10442–52.
39. Calton CM, Bronnimann MP, Manson AR, Li S, Chapman JA, Suarez-Berumen M, et al. Translocation of the papillomavirus L2/vDNA complex across the limiting membrane requires the onset of mitosis. PLoS Pathog. 2017;13:e1006200.
40. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999;18:3017–33.
41. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnau KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature. 1988;335:835–7.
42. Prouse MB, Campbell MM. The interaction between MYB proteins and their target DNA binding sites. Biochim Biophys Acta. 2012;1819:67–77.
43. Jackson J, Ramsay G, Sharrkov NV, Lium E, Katzen AL. The role of transcriptional activation in the function of the Drosophila myb gene. Blood Cells Mol Dis. 2001;27:446–55.
44. Dollard SC, Broker TR, Chow LT. Regulation of the human papillomavirus type 11 E6 promoter by viral and host transcription factors in primary human keratinocytes. J Virol. 1993;67:1721–6.
45. Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res. 1981;41:1657–63.
46. Soeda E, Ferran MC, Baker CC, McBride AA. Repression of HPV16 early region transcription by the E2 protein. Virology. 2006;351:29–41.
47. Stepp WH, Meyers JM, McBride AA. Sp100 provides intrinsic immunity against human papillomavirus infection. MBio. 2013;4:e00845–13.
48. Straub E, Dreer M, Fertey I, Iftner T, Stubenrauch F. The viral E8/E2C repressor limits productive replication of human papillomavirus 16. J Virol. 2014;88:937–47.
49. Yee C, Krishnan-Hewlitt I, Baker CC, Schlegel R, Howley PM. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol. 1985;119:361–6.
50. Münger K, Scheffner M, Huibregtse JM, et al. The CD63-Syntenin-1 complex controls post-endocytic trafficking of oncogenic human papillomaviruses. Sci Transl Med. 2014. https://doi.org/10.1111/cmi.12271.
51. Kühn U, Kühn M, Hübregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 1992;12:197–217.
52. Akgül B, Karle P, Adam M, Fuchs PG, Pišter HJ. Dual role of tumor suppressor p53 in regulation of DNA replication and oncogene E6-promoter activity of epidermodysplasia verruciformis-associated human papillomavirus type 8. Virology. 2003;308:279–90.
53. White EA, Münger K, Howley PM. High-risk human papillomavirus E7 proteins target PTEN/p14 for degradation. MBio. 2016;7:e01530-16.
54. Hwang ES, Riese DJ, Settleman J, Nilson LA, Honig J, Flynn S, et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol. 1993;67:3720–9.
55. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. 2002;21:6041–8.
56. Desaiantes C, Demeret C, Goyat S, yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. 1997;16:504–14.
57. van Doornaars K, Chen D, Chapman S, Khan J, McBride AA. Persistence of an oncogenic papillomavirus genome requires cis elements from the viral transcriptional enhancer. MBio. 2017;8:e00845
58. Leitz J, Reuschenbach M, Lohrey C, Honegger A, Accardi R, Tommasino M, et al. Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog. 2014;10:e1003957.
59. Zhou Y, Ness SA. Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed). 2011;16:1109–31.